No Data
No Data
Express News | The Committee For Medicinal Products For Human Use Of The European Medicines Agency Issued Positive Opinions Recommending An Extended Authorization For BeiGene's Tevimbra (Tislelizumab) In Gastric Or Gastroesophageal Junction Adenocarcinoma And...
BeiGene Receives Positive CHMP Opinions for TEVIMBRA as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma
Nomura Adjusts BeiGene's Price Target to HK$174.91 From HK$158.37, Keeps at Buy
Recent 7.2% Pullback Isn't Enough to Hurt Long-term BeiGene (NASDAQ:BGNE) Shareholders, They're Still up 60% Over 5 Years
BeiGene Highlights Waldenström's Macroglobulinemia Innovation at IWWM 2024
Top Gap Ups and Downs on Monday: BLCO, SIRI, ICL, HMY and More